Objective: Lidocaine acts as a local anesthetic by blocking transmembrane sodium channel permeability, but also induces the synthesis of heat shock proteins and sensitizes cells to hyperthermia. A previous study reported two cases of deep focal skin ulceration at points corresponding to depot local lidocaine injection sites after treatment with non-ablative fractional resurfacing and it was hypothesized that lidocaine had focally sensitized keratinocytes to the thermal damage of laser treatment. The objective of this study was to investigate whether lidocaine potentiates hyperthermia damage to both normal and cancerous skin cells using an in vitro model. Methods: Normal skin cell lines (fibroblasts, keratinocytes), skin cancer cell lines (melanoma, basal cell carcinoma), and a mucosal cancer cell line (cervical carcinoma) were exposed to various concentrations of lidocaine (0-0.3%) with or without hyperthermia (378C, 428C). Results: Compared to normal skin cells, we demonstrate that cancer cell lines show significantly increased cell toxicity when a moderate temperature (428C) and low lidocaine concentrations (0.1-0.2%) are combined. The toxicity directly correlates with a higher percentage of cells in S-phase (28-57%) in the cancer cell lines compared to normal skin cell lines (13-19%; R-square 0.6752). Conclusion: These results suggest that lidocaine potentiates thermal sensitivity of cell cycle active skin cells. The direct correlation between cell toxicity and S-phase cells could be harnessed to selectively treat skin and mucosal cancer cells while sparing the surrounding normal tissue. Additional research pre-clinically and clinically using several different heat sources (e.g., lasers, ultrasound, etc.) and lidocaine concentrations is needed to confirm and optimize these results. Lidocaine-enhanced hyperthermia may provide a non-invasive, alterative treatment option for highly proliferating, superficial skin, and mucosal lesions such as cancer or warts. Lasers Surg. Med. 51:88-94, 2019.
INTRODUCTION
Severe skin ulceration after non-ablative fractional laser has previously been reported at the site of 1% lidocaine depot injection despite conservative settings and adequate time and cooling between passes [1] . Topical application of lidocaine with the same moderate laser setting did not show any unwanted side effects. It was hypothesized that lidocaine sensitized the skin cells to thermal damage, however exploration of this hypothesis has not been undertaken previously. In this study, we investigate whether lidocaine could enhance the cellular damage from hyperthermia in normal and cancerous skin cells in vitro. If the combined treatment with hyperthermia and lidocaine does affect cellular damage differentially, this could represent a novel treatment option for highly proliferating superficial skin and mucosal lesions such as cancer or warts.
Skin cancer is the most common diagnosed cancer in the United States with an estimated 3.3 million cases reported annually [2, 3] . The standard treatment of choice for skin cancer is surgery, including standard excision and the more specialized Mohs micrographic surgery. While effective for many patients, surgery is accompanied with pain, scarring, the risk of wound infection, and, in the case of Mohs surgery, higher cost, and limited availability. Alternative treatments for skin cancer include topical and intralesional chemotherapy, electrodessication and curettage (ED&C), and radiation therapy. However, these alternatives may lead to lower efficacy, recurrence, significant scarring, or higher cost [2] .
Hyperthermia has been posited as an alternative, non-invasive, localized therapeutic option for cancer treatment that can induce cell death in targeted cancer cells [4, 5] . The objective of locally applied hyperthermia is to induce cell damage to the tumor area while causing minimal damage to the surrounding tissue (typically 40-448C). The effectiveness of hyperthermia is mediated by the applied temperature, length of treatment, and area of treatment. The ease of applying heat superficially makes the use of hyperthermia for skin cancer a logical target, however this has been limited by the requirement for long treatment times (>90 minutes) with moderate temperatures ($428C) [6] . The use of local anesthetics, such as lidocaine, in combination with hyperthermia has been shown to enhance hyperthermia induced cell death in vitro [7, 8] . In its traditional mechanism of action as an anesthetic, lidocaine blocks the transmembrane permeability of sodium ion channels, thus preventing the depolarization of neurons and inhibiting painful sensation [9] [10] [11] .
In this study, we investigated whether a moderate temperature (428C) in combination with non-toxic lidocaine concentrations (0.1-0.3%) enhances cell death in skin and cancer cell lines. Furthermore, we correlated the induced cell death with the cell cycle activity of the cell lines to determine if rapidly dividing cancer cells could be selectively targeted. Experiments were conducted with two normal skin cell lines (fibroblasts, keratinocytes), two skin cancer cell lines (melanoma, basal cell carcinoma), and a mucosal cancer cell line (cervical carcinoma).
MATERIALS AND METHODS

Cell Culture
Human keratinocytes (KertR), human foreskin fibroblasts (HFF1), murine basal cell carcinoma (ASZ), and human cervical cancer (HeLa) cell lines were purchased from American Type Culture Collection (ATCC, Manassas, VA). A human melanoma cell line (A375) was obtained from the laboratory of Dr. Hensin Tsao at the Massachusetts General Hospital, which was bought from American Type Culture Collection (ATCC, Manassas, VA). Cells were cultured in complete growth medium at 378C in a humidified atmosphere and 5% CO 2. Dulbecco's Minimum Essential Medium (DMEM) with 10% fetal calf serum, 100 mg/ml streptomycin and 100 U/ml penicillin (Invitrogen, St Louis, MO) was used for HFF1, HeLa, and A375, while KertR were cultured in serum free EpiLife 1 medium supplemented with human keratinocytes growth supplement (HKGS, Life Technologies, Woburn, MA), 100 mg/ml streptomycin and 100 U/ml penicillin (Invitrogen). Murine basal cell carcinoma cells (ASZ) were cultured in M154F (GIBCO, Woburn, MA) supplemented with previous chelexed heat-inactivated fetal bovine serum, 100 mg/ml streptomycin, 100 U/ml penicillin (Invitrogen) and 0.05 mM of CaCl 2 . Growth medium was changed every 3 days. Experiments were performed with exponential growing cells with low passage number (4) (5) (6) (7) (8) (9) (10) (11) (12) .
Cell Viability Assay
Cells were plated 24 hours before heat and/or lidocaine treatment in six-well plates (Becton Dickinson, Franklin Lakes, NJ). Cells were treated with a range of lidocaine concentrations (Hospira, Lake Forest, IL, 0-0.3%) for 20 minutes before heating for 10 minutes on a heating plate to 378C or 428C and incubated with fresh medium for 24 hours in a CO 2 incubator. Afterwards, cells were washed with phosphate buffered saline (PBS, Thermo Fisher Scientific, Waltham, MA) before 500 mg/ml 3-(4,5-dimethylthiazol-2-Yl)-2,5-diphenyltetrazolium bromide (MTT, Sigma, St. Louis, MO) was added for 2 hours. MTT solution was replaced with dimethyl sulfoxide (DMSO, Sigma, St Louis, MO) for 30 minutes. Viability was measured as absorbance at 570 nm using an ELISA plate reader (SpectraMax M5, Molecular Devices, San Jose, CA).
Cell Cycle Analysis
Cell cycle was determined by flow cytometry [12] . Briefly, cells were trypsinized, washed with PBS and fixed with ice-cold 70% ethanol (48C) for at least 1 hour. Afterwards, cells were washed with PBS and resuspended in 0.1 mg/ml propidium iodide solution (AnaSpec Inc., San Jose, CA), containing 0.5 mg/ml RNase and 0.1% Triton X detergent. The DNA content of up to 20,000 cells was measured by flow cytometry (FACSCalibur, Becton Dickinson, Franklin Lakes, NJ). The cell cycle was analyzed with a flow cytometry software (FlowJo v10, Ashland, OR) using the Watson pragmatic univariate model with constraints on the mean G 2 peak (G 2 ¼ 2 Â G 1 ).
Statistical Analysis
Statistical analysis was performed by using GraphPad Prism software (GraphPad Software version 7.03, La Jolla, CA). For the data in Figure 2 we performed an unpaired, two-tailed student's t-test and for the data in Figure 3 we performed an ordinary one way ANOVA test. P values <0.05 were considered statistically significant.
RESULTS
Heating Time
Fibroblasts were heated to a pre-set temperature for 10 minutes and temperature was measured every minute. This resulted in an asymptotic increase of the temperature which reached the set temperature after approximately 6-7 minutes (Fig. 1a) . Figure 1b shows a temperature dependent decrease of cell viability for fibroblasts after a total heating time of 10 minutes at various temperatures (up to 708C). Moderate heating (<448C) caused only a minor cell viability loss of about 10%. Higher temperatures (>448C) significantly increased the viability loss up to 98%. For this study, moderate heating to 428C with non-significant cytotoxicity was chosen to evaluate the cytotoxicity for combined treatment in the various cell lines.
Cell Viability After Single and Combined Treatment
Experiments were performed at 378C and 428C with or without lidocaine in a range of 0-0.3%. Fibroblasts and keratinocytes show a low toxicity to the combined treatment with 428C and low concentration of lidocaine (0.1-0.2%). In contrast, the melanoma and cervical cancer cell lines expressed a significant decrease in cell viability compared to fibroblasts and keratinocytes at 0.2% lidocaine (P < 0.01, Fig. 2) . The basal cancer cell line was the most sensitive to the combined treatment, showing significant cell toxicity even with 0.1% lidocaine concentrations (P < 0.0001, Fig. 2) .
Direct comparison of all cell lines highlights the increased sensitivity of cancer cells toward the combined hyperthermia-lidocaine treatment in comparison to normal skin cell lines (Fig. 3) . At a temperature of 428C and lidocaine concentration of 0.2%, fibroblasts and keratinocytes showed only a minor loss in cell viability of 10-20%, while the cancer cell lines exhibited a significantly higher viability loss ranging from 50 to 95% (P < 0.05).
Cell Cycle Analysis
Cell cycle analysis for all cell lines is shown in Figure 4 and Table 1 . All cancer cell lines had a higher percentage of cells in S-phase compared to normal skin cell lines (melanoma-39%, cervical cancer-28.5%, and basal cell carcinoma-56.1% versus fibroblasts-13.3% and keratinocytes-19.2%). For hyperthermia treatment alone, no correlation was found between the cell toxicity and the amount of cells in S phase (r 2 ¼ 0.01203). In contrast, the combined treatment (428C plus 0.2% lidocaine) revealed a strong correlation (r 2 ¼ 0.6752) between cytotoxicity and cell cycles phase, showing that cell lines with a high S-phase content were more sensitive toward the combined treatment.
DISCUSSION
In this study, the cytotoxic effect of moderate hyperthermia in combination with low lidocaine concentrations on skin and mucosal cell lines was assessed. Combining hyperthermia with lidocaine caused a compounded decrease in cellular viability compared to each treatment alone. Our findings support and expand upon prior studies. It has been shown that prolonged hyperthermia (>30 minutes) at 458C caused significant cell toxicity in melanoma and non-melanoma skin cancer cells [6] . However, we highlighted that significant cell toxicity can be achieved with short treatment time (10 minutes) and moderate temperature (428C) when combined with lidocaine. Importantly, this short treatment time fits within current outpatient dermatology visit time constraints (approximately 15 minutes per patient). While lidocaineenhanced hyperthermia has been utilized in hematologic and hepatic cancer cell lines [8, 13] , skin cancer cell lines have not been previously evaluated. We further built upon this data with comparative analysis of normal and skin cancer cells and correlation of cell cycle with combined treatment to selectively target rapidly proliferating cutaneous lesions.
The potential mechanisms by which lidocaine enhances hyperthermia have been investigated. Yun et al. [14] had shown that lidocaine induces cell membrane permeability by acting on the hydrocarbon backbone of the lipid bilayer while altering the dipole orientation via hydrogen-bond lidocaine, a statistically significant decrease in cell viability is seen for fibroblasts versus cervical cancer cells (P < 0.05), and keratinocytes versus cervical cancer cells (P < 0.01) and versus basal cell carcinoma (P < 0.05). At 0.2% lidocaine, a statistically significant decrease in cell viability is seen for fibroblasts versus melanoma (P < 0.05), versus cervical cancer cells (P < 0.001), and versus basal cell carcinoma (P < 0.0001); and keratinocytes versus melanoma (P < 0.01), versus cervical cancer cells (P < 0.0001), and versus basal cell carcinoma (P < 0.0001). At 0.3% lidocaine, a statistically significant decrease in cell viability is seen for fibroblasts versus cervical cancer cells (P < 0.01), and versus basal cell carcinoma (P < 0.01); and keratinocytes versus melanoma (P < 0.001), versus cervical cancer cells (P < 0.0001), and versus basal cell carcinoma (P < 0.0001). Error bars show standard error of the mean (SEM).
disruption. This lidocaine-induced membrane permeability allows for other cellular disruptions, including phosphatidylserine externalization, increase in intracellular Ca 2þ ions, depolarization in membrane potential, and excessive production of reactive oxygen species (ROS) [15] . These cellular changes are characteristic of early stage apoptosis.
Separately, hyperthermia can inhibit DNA repair mechanisms, such as homologous recombination and non-homologous end joining [16] . Proteins, such as BRCA2, that aid in DNA repair, are degraded upon moderate temperature ($428C), thus inhibiting the proper function of these repair mechanisms [16] . The inhibition of these repair mechanisms and the disruption of other cellular pathways (e.g., Ca 2þ homeostasis, misfolded proteins, etc.) could induce cell death via ER-mediated apoptosis, as the ER is responsible for many of the cellular functions disrupted by lidocaine and hyperthermia [6] . Our findings show a positive correlation between the percentage of cells in S-phase and cell toxicity to the combined treatment. Cellular DNA is more accessible immediately before and during cell division, which may lead to increased DNA damage during heating. Therefore, the various mechanisms of cell injury induced by hyperthermia and lidocaine might explain the synergistic increase in cytotoxicity. Table 1 . Cancer cell lines have a higher percentage of cells in S-phase compared to normal skin cells.
Our data suggest that the cell toxicity of the combined treatment is cell-cycle dependent. Compared to cancer cells with exponential growth, confluent non-dividing cells show comparatively much lower cytotoxicity (data not shown). Previous studies also showed that cells in the midto late-S-phase having increased susceptibility to hyperthermia [17, 18] . These observations suggest actively dividing cells can be selectively targeted. Comparing the toxicity within the five tested cell lines revealed that the cancer cells, which have an increased portion of cells in the S-phase, are more susceptible to the combined treatment (Fig. 5) .
For this in vitro study, we utilized low lidocaine concentrations (0.1-0.3%), which are a magnitude lower compared to the commonly used clinical doses of injectable (1-2%) or topical (2-4%) formulation. After topical application or injection, lidocaine diffuses through the interstitial space and lymphatic system, resulting in a quick dilution of the initial concentration. This dilution can be slowed by the addition of epinephrine to constrict cutaneous blood vessels. Further in vivo studies will be needed to optimize the concentration and temperature conditions for the combined hyperthermia-lidocaine treatment.
The data presented in this study suggest that moderate hyperthermia in combination with low lidocaine concentrations could provide a new, non-invasive treatment modality for hyperproliferative cutaneous lesions, such as skin or mucosal carcinomas or warts. With the incidence of skin cancer increasing, alternative, non-invasive treatment options are needed. A previous study using a 1,064 nm long-pulsed Nd:YAG laser to treat BCC has shown high clearance after only one treatment and at high fluences [4] . However, low fluences in combination with low doses of local anesthetics has not been studied in skin and might provide high efficacy and specificity while sparing the surrounding normal tissue. Importantly, significant in vitro changes in our study were noted after only 10 minutes of treatment, which has implications for efficiency of this modality if adapted for outpatient treatment. Further preclinical and clinical studies utilizing energy-based devices (e.g., long-pulsed 1,064 nm Nd: YAG laser with low fluence, radiofrequency, or focused ultrasound) as a heat source are needed to determine whether this modality is efficacious, well-tolerated, costeffective, and minimizes scarring.
CONCLUSION
In summary, we found that moderate temperatures (428C) in combination with low concentrations of lidocaine (0.2%) causes significantly increased skin cancer cell death. In addition, we demonstrated a direct correlation between increased cell death and high percentage of cells in S-phase. To determine mechanism of cell death and to optimize our results, further studies need to be conducted in vitro and in vivo. Clinical studies involving various heat sources, including lasers, and radiofrequency devices, and low concentrations of lidocaine are needed to determine treatment efficacy.
